Charles F Schuler1,2, Carmen Gherasim3, Kelly O'Shea1,2, David M Manthei3, Jesse Chen1,4, Don Giacherio3, Jonathan P Troost5, James L Baldwin1,2, James R Baker1,2,4. 1. Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America. 2. Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, MI, United States of America. 3. Department of Pathology, University of Michigan, Ann Arbor, MI, United States of America. 4. Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI, United States of America. 5. Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI, United States of America.
Abstract
BACKGROUND: As COVID-19 vaccines become available, screening individuals for prior COVID-19 infection and vaccine response in point-of-care (POC) settings has renewed interest. We prospectively screened at-risk individuals for SARS-CoV-2 spike and nucleocapsid protein antibodies in a POC setting to determine if it was a feasible method to identify antibody from prior infection. METHODS: Three EUA-approved lateral flow antibody assays were performed on POC finger-stick blood and compared with serum and a CLIA nucleocapsid antibody immunoassay. Variables including antibody class, time since PCR, and the assay antigen used were evaluated. RESULTS: 512 subjects enrolled, of which 104 had a COVID-19 history and positive PCR. Only three PCR-positive subjects required hospitalization, with one requiring mechanical ventilation. The POC results correlated well with the immunoassay (93-97% sensitivity) and using serum did not improve the sensitivity or specificity. CONCLUSIONS: Finger-stick, POC COVID-19 antibody testing was highly effective in identifying antibody resulting from prior infections in mildly symptomatic subjects. Using high-complexity serum immunoassays did not improve the screening outcome. Almost all individuals with COVID-19 infection produced detectable antibodies to the virus. POC antibody testing is useful as a screen for prior COVID-19 infection, and should be useful in assessing vaccine response.
BACKGROUND: As COVID-19 vaccines become available, screening individuals for prior COVID-19infection and vaccine response in point-of-care (POC) settings has renewed interest. We prospectively screened at-risk individuals for SARS-CoV-2spike and nucleocapsid protein antibodies in a POC setting to determine if it was a feasible method to identify antibody from prior infection. METHODS: Three EUA-approved lateral flow antibody assays were performed on POC finger-stick blood and compared with serum and a CLIA nucleocapsid antibody immunoassay. Variables including antibody class, time since PCR, and the assay antigen used were evaluated. RESULTS: 512 subjects enrolled, of which 104 had a COVID-19 history and positive PCR. Only three PCR-positive subjects required hospitalization, with one requiring mechanical ventilation. The POC results correlated well with the immunoassay (93-97% sensitivity) and using serum did not improve the sensitivity or specificity. CONCLUSIONS: Finger-stick, POC COVID-19 antibody testing was highly effective in identifying antibody resulting from prior infections in mildly symptomatic subjects. Using high-complexity serum immunoassays did not improve the screening outcome. Almost all individuals with COVID-19infection produced detectable antibodies to the virus. POC antibody testing is useful as a screen for prior COVID-19infection, and should be useful in assessing vaccine response.
Authors: Halie M Rando; Christian Brueffer; Ronan Lordan; Anna Ada Dattoli; David Manheim; Jesse G Meyer; Ariel I Mundo; Dimitri Perrin; David Mai; Nils Wellhausen; Covid-Review Consortium; Anthony Gitter; Casey S Greene Journal: ArXiv Date: 2022-04-26
Authors: Kseniya V Serebrennikova; Nadezhda A Byzova; Anatoly V Zherdev; Nikolai G Khlebtsov; Boris N Khlebtsov; Sergey F Biketov; Boris B Dzantiev Journal: Biosensors (Basel) Date: 2021-12-10